Alle Kiffer aufgepasst! Das hier ist Eure Aktie!!! - 500 Beiträge pro Seite

[Polecat]

Das Unternehmen ist vor etwa einem halben Jahr an die Börse gegangen. Das besondere an diesem Pharmaunternehmen ist, dass sie grundsätlich nur Medikamente herstellen, die auf THC-Verbindungen basieren.

Vor etwa 3 Jahren ist mir mal ein Flyer in die Hände gefallen auf dem sehr glaubhaft beschrieben wurde, dass 80%!!! aller momentan auf dem Markt erhältlichen Medikamente durch Hanf-Essenzen ersetzt werden können. Na wenn sich da kein Markt auftut...

Nächster Kaufgrund: Nach "Missgeschicken" wie z.B. dem letzlich bekannt gewordenem Fall bei Bayer (Libobay) ist die Nachfrage nach auf natürlicher Basis hergestellten Medikamenten stark angewachsen.

Sollte sich dazu auch noch die Gesetzeslage in anderen europäischen Ländern ändern, dann ist diese Aktie wohl kaum am Boden zu halten.

Nix für Daytrader oder Leute die das schnelle Geld machen wollen. Allerdings genau das richtige für jemanden wie mich... gemütlich n paar Stücke kaufen und liegenlassen. Die Aktie wird ihren Weg machen, da bin ich mir sicher!

GW Pharmaceuticals
WKN: 693692

Gruß an alle THC-Freunde ,
Polecat

[bertthx]

...na das ist doch mal Licht am Ende des Tunnels, fraglich
allerdings, ob das dt. Politiker in ihre Betonköpfe bekommen.

Ich werde sie beobachten.

See you later...

[Furan]

THC löst leider nicht alle probleme,und ich denke auch keine 80%.
es gibt massenweise verschiedenster wirkstoffe,die THC (tetrahydrochlorid)mit sicherheit nicht ersetzen kann.
wäre schön, aber auch zu einfach.

[spekulump]

Der Junge hat keine Ahnung.

das ist tetra hydro cannabinol

-SL-

[Furan]

sorry soll tetrahydrocanabinol heißen

[Polecat]

Hier noch 2 Adressen, um sich mit Infos einzudecken:

http://www.gwpharm.com
http://atlas.pharmalicensing.com/company/dc/2785

Viel Spaß beim Stöbern,
Polecat

[tetrahydrocannabinol]

Furan

Die Hanfpflanze gilt wegen ihrer vielfältigen Nutzbarkeit seit 5 000 Jahren als wertvolle Kulturpflanze. Sie enthält das Rauschmittel THC (Tetrahydrocannabinol).......

gruß
THC

[Furan]

is mir doch bekannt.
der kleine schreibfehler wurde von mir doch auch nach ein paar sekunden korrigiert.
kann doch mal vorkommen,oder?
war da irgendwie bei den schmerzmitteln: cocainhydrochlorid
die frage ist doch aber: wie soll THC massenweise andere wirkstoffe ersetzten?
anstatt auf dem tetrahydrocannabinol rum zu hacken
hätte ich dazu gerne mal ne gute antwort.

[Polecat]

@Furan

die Frage sollte eher lauten: Warum brauchen wir so viele andere Wirkstoffe, wenn es Hanf (bzw. THC) gibt?

Sieht man sich die Entwicklung der Chemie-Konzerne wie Bayer, DuPont, Roche usw. mal im Verhältnis zur Gesetzeslage der entsprechenden Jahre an, wird eines sehr deutlich: Chemie-Konzerne haben eine viel zu große Lobby in der Politik.

Es ist durch mehrfache wissenschaftliche Studien bewiesen, dass Krankheiten wie z.B. grauer Star geheilt werden können. Dazu gilt der Wirkstoff THC als sehr gute Unterstützung im Bereich der Krebs- und HIV-Therapie.
Aber warum wird kaum THC eingesetzt? Und warum ist es immer noch nicht legal in Deutschland?
Die Antwort liegt auf der Hand.

Übrigens... soweit ich richtig informiert bin wurde Heroin von Bayer erfunden.

Gruß,
Polecat

[Depotmaster]

Ich poste mal eben, um die Aktie nicht zu vergessen...

[dawad]

bin auch stark der meinung das thc die meisten medikamente ersetzen kann.natürlich reicht thc allein nicht aus.
ich bin schon immer der aufassung das es keine wirklichen wirksamen medikamente gibt .
drogen sind ja verboten drum schuffen die grossen konzerne unter der führung mächtiger lobbis medicin die den mensch abhängig macht aber nicht nur von der eingenommenen medicin sondern auch von den ganzen anderen kapital scheiß
.mein posting natur ist die einzige droge und die ist nur schädlich wenn man sie ignoriert.
kiffen koksen aktien kaufen

[Polecat]

11th April 2002

GW Expands Phase Three Clinical Trials Programme

GW Pharmaceuticals plc, the company developing a portfolio of non-smoked, cannabis-based prescription medicines, announces the commencement of Phase Three clinical trials in four new indications. These four new Phase Three trials bring the total number of Phase Three trials being conducted by GW to seven. In total, these trials will involve approximately 600 patients.

These latest four Phase Three trials will examine the effectiveness of cannabis based medicines in the following medical conditions:

Pain in Spinal Cord Injury
Pain & Sleep in Multiple Sclerosis (MS) and Spinal Cord Injury
Neuropathic pain in MS
General neuropathic pain (as evidenced by allodynia*)
The trials are double-blind and placebo controlled, and are taking place at a number of centres around the UK. The cannabis-based medicine is being administered by means of a sublingual (under-the-tongue) spray.

GW now has a broad Phase Three trials programme simultaneously examining a range of different symptoms and medical conditions. This programme is designed to generate safety and efficacy data to allow GW to seek regulatory approval for its cannabis-based medicines in a range of medical conditions. Results from the first few trials to complete are intended to form the basis of GW`s first regulatory submission to the Medicines Control Agency, scheduled for 2003.

The four new trials announced today supplement the three Phase Three trials already in progress, all of which continue to recruit well. These trials are:

Multiple Sclerosis (Multiple symptoms)
Cancer pain
Brachial plexus injury (a severe form of nerve-damage pain)
Dr Geoffrey Guy, Executive Chairman of GW Pharmaceuticals, commented, "GW is pursuing a parallel development strategy for its Phase Three trials programme. This strategy incorporates a large number of trials designed to provide the most rapid advancement towards regulatory approval whilst at the same time minimising the risk of delay. To this end, we expect to continue the roll out of Phase Three trials during the course of this year.

"The start of four new Phase Three clinical trials heralds the achievement of another key milestone in our progress towards first regulatory submission for our products. Target timescales for our lead products remain on track and we are aiming to present data for Product Licence Approval in 2003."

In the event of a Product Licence being granted, the UK Government has indicated that it will be willing to amend the Misuse of Drugs Act 1971 to allow the prescribing of a cannabis-based medicine. This will allow sufferers of MS, Spinal Cord Injury and other neurological disorders to experience the medical benefits of cannabis without unwanted psychoactive side effects, and without the health dangers associated with smoking.

---

Gruss,
Polecat

[Polecat]

wie man sieht, stehen mehrere Projekte vor der Fertigstellung. Die Aktie wird immer interessanter...

Gruss,
Polecat

[Polecat]

Ein paar Unternehmensinformationen für zwischendurch...

Management Team

GW has a team with a proven track record and relevant experience and is well placed to research and develop the potential of non-smoked prescription cannabis-based medicines. Dr Geoffrey Guy and Dr Brian Whittle, GW`s Executive Director and Scientific Director respectively, together founded Phytopharm plc in 1989, a plant medicines company now listed on the London Stock Exchange. Dr Guy and Dr Whittle also worked together at Ethical Holdings plc, a drug delivery company founded in 1985 by Dr Guy and which obtained a NASDAQ listing in 1993. The management team combines pharmaceutical, medical, regulatory, botanical and business knowledge.


History

November 1997:
British Medical Association publishes its report "Therapeutic Uses of Cannabis".

November 1998:
House of Lords Select Committee on Science and Technology publishes its report: "Cannabis: The Scientific and Medical Evidence".
http://www.publications.parliament.uk/pa/ld199798/ldselect/l…

March 1999:
Institute of Medicine publishes its report "Marijuana and Medicine: Assessing the Science Base".
http://www.nap.edu/readingroom/books/marimed/

April 1998:
Dr Geoffrey Guy (Chairman of GW) licensed by the Home Office to "cultivate, produce, possess and supply cannabis for research purposes".

August 1998:
First cannabis plant sown by GW at the secure glasshouse in a secret location in the South East of England.

August 1999:
Cannabis plant number 20,000 is potted at the secure glasshouse.

September 1999:
GW and the Health & Safety Executive (HSE) carry out the first Phase I clinical trial of GW`s cannabis based medicines in healthy volunteers in London.

April 2000:
The Medicines Control Agency (MCA) issues GW with a Clinical Trial Exemption (CTX) which is the document required before a Phase II clinical trial of a medicine can be carried out in patients in the UK.

May 2000:
The Department of Trade and Industry (DTI) awards GW a Smart Award for Innovation and Technology for the development of a secure electronic inhaler to deliver cannabis-based medicines.

May 2000:
First Phase II trial of GW`s cannabis-based medicines in neurogenic pain begins at The James Paget Hospital in Great Yarmouth and is run by Dr William Notcutt, Consultant Anaesthetist.

July 2000:
Phase II clinical trials into cannabis-based medicines in Multiple Sclerosis and Spinal Cord Injury begin at GW`s Oxford trial centre.

August 2000:
University of California San Diego (UCSD) receives a grant of US$ 3million per year for 3 years from the State of California to establish the Centre for Medicinal Cannabis Research. GW makes a grant to assist with this research effort.

September 2000:
Phase II clinical trial of GW`s cannabis based medicines to treat bladder dysfunction in patients with advanced multiple sclerosis begins at The National Hospital for Neurology and Neurosurgery. This trial is sponsored by The Medicinal Cannabis Research Foundation.

September 2000:
Phase II clinical trials begin in a variety of medical conditions, including Multiple Sclerosis, Spinal Cord Injury, Rheumatoid Arthritis and Arachnoiditis, at GW`s trial centre at the Princess Elizabeth Hospital in Guernsey.

September 2000:
Cannabis plant number 50,000 is potted at the secure glasshouse.

October 2000:
GW enters into a development collaboration with a US company with considerable expertise in the development of plant-based medicines.

December 2000:
The IND submitted by GW to the Canadian regulatory authorities is accepted.

March 2001:
House of Lords Select Committee on Science and Technology publishes its report "Therapeutic Uses of Cannabis" which reviews progress since its 1998 report on medicinal cannabis.

May 2001:
GW issues a press release announcing extension of GW`s programme into Phase III in the UK and approval to commence initial clinical trials in Canada.

May 2001:
GW issues a press release announcing it`s intention to float on the Alternative Investment Market (AIM) of the London Stock Exchange.

June 2001:
GW issues a press release announcing its successful £25m placing and admission to the Alternative Investment Market (AIM) of the London Stock Exchange.

August 2001:
GW issues a press release announcing the start of clinical trials in Canada - the company`s first trial outside the UK.

September 2001:
GW announces preliminary clinical trial results to the American Academy of Pain Management.


Gruss,
Polecat

[Polecat]

Tachchen

nur mal eben ein Posting, um mal wieder an die Aktie zu erinnern.

Hab letztens einen interessanten Bericht über einen Modellversuch hier in Deutschland gesehen, in dem es um die Behandlung von Menschen mit sog. "Tics" ging. (Torret-Syndrom)

Es wurde darin unter anderem von einem Kinderpfleger berichtet, der mit Hilfe von Medizin auf Cannabisbasis in der Lage war, seine Ausbrüche zu kontrollieren.

Für mich ein weiterer Beweis dafür, wie vielfältig einsetzbar, diese Pflanze ist... und ein Grund, mehr GW-Aktien zu kaufen.

Gruss,
Polecat

[Polecat]

und hier mal ein paar Zahlen aus der News vom 13.06.02:

Interim Results For The Six Months To 31 March 2002.

Highlights

Phase III trials programme for cannabis-based medicines remains on track
Two new Phase III trials targeting specific symptoms of Multiple Sclerosis announced today
Total of nine Phase III trials now underway, including Multiple Sclerosis, Spinal Cord Injury, Neuropathic Pain, Cancer Pain
Recruitment in the leading four Phase III trials now over 85% complete and on schedule
Ongoing positive results from Phase II trials
Establishment of Cannabinoid Research Institute and appointment of Professor Roger Pertwee, one of the world’s leading cannabinoid scientists, as Director of Pharmacology
Arrangements for commercial scale cultivation, extraction and final product manufacture in place in preparation for market launch
New Home Office-backed collaboration with National Addiction Centre for use of GW’s secure drug dispensing technology in prescribing of methadone and diamorphine (being announced separately today)
Net loss for the six months to 31 March 2002 of £5.3m, in line with budget
Cash reserves at 31 March 2002 of £21.1m
Dr Geoffrey Guy, Executive Chairman of GW Pharmaceuticals, said: “Progress across the breadth of the Group’s activities has continued according to expectation in the first half of the financial year and GW’s development programme remains firmly on track. Looking ahead, the first Phase III clinical trials should report results towards the end of this year and, if successful, the results of these trials will form the basis of our first product submission to the Medicines Control Agency. With arrangements in place with respect to commercial scale cultivation, extraction and manufacturing, GW is on track to be market-ready well ahead of our planned market launch in early 2004.

“In addition, the new product development programmes for the treatment of heroin addiction being announced separately today provide a significant exciting new market opportunity for the Group.”

A presentation for analysts is taking place today at 09.00 at Weber Shandwick Square Mile, Aldermary House, 15 Queen Street, London EC4. An audio webcast of the presentation will be available on GW’s website at www.gwpharm.com from 15.00 today.



Interim Results For The Six Months To 31 March 2002

HALF YEAR REVIEW
GW continued to make good progress with its development programme in the first six months of the financial year. The Company’s clinical trials programme remains on track and investment and expenditure remain in line with forecasts.

Phase III Update
Since the beginning of this financial year, GW has commenced eight Phase III clinical trials to support our first regulatory applications. The start of the latest two of these trials is being announced today. These new trials target specific symptoms of Multiple Sclerosis – spasticity and bladder dysfunction.

Including the first Multiple Sclerosis trial which commenced in May 2001, GW now has nine Phase III trials underway. These trials will involve approximately 650 patients.

The trials are progressing to schedule with recruitment in the leading four Phase III trials now over 85% complete.

GW now has in place a broad Phase III trials programme simultaneously examining a range of different symptoms and medical conditions. This programme is designed to generate safety and efficacy data to allow GW to seek regulatory approval for its cannabis-based medicines in a range of medical conditions. Results from the first few trials to complete are intended to form the basis of GW`s first regulatory submission to the Medicines Control Agency, scheduled for 2003. Target timescales for our lead products, as stated at the time of the Company’s flotation on the Alternative Investment Market (AiM) in mid 2001, remain on track.

The Phase III trials programme is examining the effectiveness of cannabis-based medicines in the following medical conditions:

Multiple Sclerosis (multiple symptoms)
Cancer Pain
Brachial plexus injury (a severe form of nerve-damage pain)
Pain in Spinal Cord Injury
Pain & Sleep in Multiple Sclerosis and Spinal Cord Injury
Neuropathic pain in Multiple Sclerosis
General neuropathic pain (as evidenced by allodynia - a painful response to typically non-painful stimulus)
All trials are double-blind and placebo controlled, and are taking place at hospital centres around the UK. Certain trials also include centres in other European countries. The cannabis-based medicine is being administered by means of an oro-mucosal spray.

Phase II Update
GW’s Phase II trials have involved approximately 120 patients to date. Of the first 109 patients, 88 completed the acute phase, of which 86 elected to continue long term.

In January 2002, GW presented an updated set of data from Dr Notcutt’s Phase II trial in Multiple Sclerosis and Spinal Cord Injury patients. This data showed statistically significant improvement in chronic pain even in small patient numbers. Also in January, GW presented data from a Phase II trial examining the effects of cannabis-based medicines on bladder function in MS patients. Initial positive results from this study have been presented by the trial investigators at scientific symposia. The results demonstrated the potential for cannabis medicines to produce significant improvements in a range of lower urinary tract symptoms including incontinence in MS patients. This result is not only applicable for MS but indicates potential in the wider incontinence market, a very substantial market in its own right.

New previously unreleased data from Dr Robson’s and Professor Wade’s Phase II trial in 24 Multiple Sclerosis patients is currently being prepared for publication. Key findings from this study are that improvements have been seen across a range of MS symptoms, several of which have reached statistical significance despite the small patient numbers. Perhaps most importantly, data from this study have revealed the potentially exciting properties of GW’s plant extract containing principally the non-psychoactive cannabinoid, cannabidiol (“CBD”). The CBD extract product outperformed other products in relieving pain and GW is now examining the potential incorporation of CBD into larger MS trials.

Following data from early Phase II trials, which demonstrated an apparent improvement in duration and quality of sleep, GW commissioned a specific Phase II study at a sleep laboratory in eight subjects to investigate this matter further. Encouragingly, the study showed that cannabis-based medicine produced no pathological effects on the process of normal sleep. The results suggest that rebound insomnia, a common problem with hypnotic drugs such as benzodiazepines, would not be expected to occur to any significant degree following cessation of long-term treatment with cannabis-based medicine. Interestingly, CBD and tetrahydrocannabinol (“THC”) had rather different effects on the central nervous system, and this interaction resulted in some useful consequences, in particular it was shown that CBD modulated certain effects of THC.
Positive results have also been presented from an exploratory post-operative pain study in patients post hysterectomy. Pain relief in the immediate post-operative period may provide an additional potential market for GW’s products not previously identified in the company’s prospectus. A pilot study is due to commence shortly, which may be followed by a larger Phase III study.
Importantly, the Phase II data generated to date continues to provide confidence in the Phase III programme being undertaken and indeed has revealed additional unexpected findings which may yield potential new product and market opportunities.

Regulatory Affairs
During the period, GW received its first regulatory approval from the Irish Medicines Board to carry out clinical trials in Ireland. Permissions have also been received to carry out clinical trials in Belgium. Meetings with regulatory authorities around Europe continue and are proving helpful in allowing us to form a strategy to secure regulatory approval throughout Europe following the first UK approval.

Cannabinoid Research Institute
In March, GW announced that Professor Roger Pertwee, Professor of Neuropharmacology at the University of Aberdeen, has joined GW’s senior management team as Director of Pharmacology. Professor Pertwee is one of the world`s leading cannabinoid scientists, having researched this area for over 30 years, and is the author of over 220 publications. In his role at GW, Professor Pertwee will focus on pharmacology in support of the Group`s clinical trials programmes and novel research, including the investigation of new therapeutic areas.

The appointment marks the first step in the planned establishment by GW of a new research entity - the Cannabinoid Research Institute. The Institute will be a distinct division within the Company and its activities will be directed by Dr Philip Robson, GW’s Medical Director. The Institute will allow GW to expand its operations from clinical and pre-clinical work into fundamental cannabinoid research.

It is our aim that GW should occupy the centre ground of cannabinoid science. By establishing the Cannabinoid Research Institute, we are building a bridge between commercial enterprise and academia. We are confident that this is the best way for GW to undertake fundamental science, and to investigate the future commercial opportunities which may arise with phytocannabinoids, which occur in plants, as well as synthetic cannabinoids and also endocannabinoids, which occur naturally within the human body.

We hope over time to involve other collaborators, so that scientists from inside and outside GW can conduct research into the mammalian cannabinoid system and potential therapeutic candidates for cannabis-based medicines.

Operations
Activity in the first half of the financial year has been concentrated on preparing GW’s cultivation and production capabilities for market launch. All key arrangements relating to commercial scale production are now in place.

An additional indoor cultivation facility has now been completed and is operational. This facility has doubled our growing capacity to over 30 tonnes of plant material per year. We have entered into arrangements with a third party contractor to cater for a significant further step-up of growing capacity (doubling current capacity to 60 tonnes of plant material) to cater for product launch. This arrangement also covers expansion to cater for potential future cultivation requirements for worldwide product sales.

GW’s extraction facility has been upgraded to meet appropriate standards of Good Manufacturing Practice (“GMP”) ahead of product launch. This facility can cater for significant commercial sales of product. Arrangements are also in place with a contract manufacturing partner with regard to establishing commercial scale GMP final product manufacturing facilities. This will meet production needs for significant commercial quantities of product.

Public Affairs
We were pleased to welcome the announcement by the UK Department of Health that it has recommended that GW’s cannabis-based medicines be included in the list of drugs to be reviewed by the National Institute for Clinical Excellence (“NICE”) in 2003 ahead of possible provision of the Group’s medicines by the National Health Service. Recommendation by NICE would further smooth the way for cannabis-based medicines to be available nationwide to NHS patients on prescription, assuming our current trials are successful.

Advanced Dispensing System
The Advanced Dispensing System (“ADS”) technology has been under development by GW for a number of years for use with its cannabis-based medicines. This proprietary technology is wholly owned by GW. GW has recognised the broad commercial potential of this technology and has developed it so that it can be applied to a wide range of drugs in a range of dosage forms.

ADS comprises a hand-held intelligent device which can dispense a range of drugs and dosage forms housed in a proprietary medicinal cartridge format. The devices can communicate in real time through proprietary software systems to back-end users through existing telecommunication technologies.

ADS provides pharmaceutical companies, doctors, clinicians and others the ability to monitor and, if required, control drug usage in real time. The technology also provides a secure and tamper-proof means of dispensing controlled drugs. ADS has the potential, therefore to enhance a drug’s safety, prevent diversion, provide greatly increased flexibility in prescribing patterns, permit the monitoring of a patient’s progress remotely and the adaptation of prescribing regimes on a day by day basis as required, and provide information on natural patterns of consumption of prescribed drugs in the community.

Methadone/Diamorphine Programme
GW is today announcing a major new Home Office-backed initiative in collaboration with Professor John Strang, Director of the National Addiction Centre and senior drugs adviser to the UK Government. This initiative aims to provide a significant advance in the treatment of drug dependency using GW’s ADS technology. The initiative will run in parallel with GW’s core cannabis-based pharmaceutical development programme.

It is recognised by the UK Government that treatment of drug addiction has a major impact on crime reduction and a key policy objective at present is to increase the participation of problem drug misusers in drug treatment programmes. Treatment focuses on the use of methadone and diamorphine but there remains grave concern at the potential for abuse of these controlled drugs. The Home Office has recognised that GW’s ADS system could make a significant contribution both in reduction of diversion and improvement in general treatment compliance. The Home Office has therefore provided its endorsement and support for this programme.

The programme provides GW with at least two new product opportunities. The near term opportunity relates to new improved methadone dosage forms incorporated into the ADS system. Trials in this area are expected to commence in the coming few months and could, if successful, lead to rapid roll-out of GW’s product into addiction centres across the UK. The diamorphine opportunity is longer term.

The potential market for GW is considerable. There are an estimated 200,000-250,000 heroin addicts in the UK alone, of which just 30,000 now use methadone treatment. The scale of the problem is similar across all European countries. The Home Office has stated that it believes ADS would allow for much larger numbers of addicts to receive effective treatment. Current government funding on treatment services for drug misusers in the UK is approximately £230m and is expected to rise to about £400m next year under existing expansion plans.

In addition, since the drugs being incorporated into the ADS technology are already approved drugs, there is a greater probability of success than with conventional drug development programmes.

Financial Review
In the six months to 31 March 2002 GW made a net loss after tax of £5.3m compared to £4.8m in the second half of the last financial year and £2.0m in the comparable period last year. The increase over the prior periods is due to the planned increase in all the Company’s activities and was in line with our budget.

Research and development expenditure increased to £5.1m (2001: H2 £4.7m; H1 £2.0m). This increase reflects the rapid advancement of our clinical trials programme and the necessary associated activities.

Management and administrative expenses (including amortisation of goodwill) increased to £1.1m (2001: H2 £0.8m; H1 £0.3m). The rate of increase in these costs has slowed significantly reflecting the fact that the majority of the required infrastructure was put in place during the latter part of last financial year.

Operating losses of £6.2m (2001: H2 £5.4m; H1 £2.3m) were reduced by interest income of £0.47m (2001: H2 £0.40m; H1 £0.11m), due to the significant increase in funds following the IPO last summer, and an R&D tax credit of £0.43m (2001: H2 £0.20m; H1 £0.15m).

Net cash outflow before management of liquid resources and financing was £4.5m (2001: H2 £4.1m; H1 £2.5m). At 31 March 2002 GW had cash and short term deposits totalling £21.1m.

Capital expenditure incurred in the period was £0.42m (2001: H2 £0.43m; H1 £0.44m) comprising largely the continuing investment in our cultivation, production and manufacturing facilities.

Headcount as at 31 March 2002 was 102 compared to 85 at 30 September 2001.

Prospects
The second half of this year represents a very exciting time for GW. The furthest advanced of our Phase III trials will near completion and, shortly thereafter, we hope to submit our first product licence application to the Medicines Control Agency in early 2003 as planned. We also look forward to further expanding our cannabinoid interests. In addition, we expect the development of our new products for the treatment of drug dependency to make good progress.



Consolidated profit and loss account
for the six months ended 31 March 2002

Six months ended Six months ended Year ended
31-Mar 31-Mar 30-Sep
Notes 2002 2001 2001
Unaudited Unaudited Audited
£000’s £000’s £000’s

Turnover — — —
Research and development costs (5,051) (1,990) (6,642)
Management and administrative expenses (1,144) (312) (1,083)

Operating loss (6,195) (2,302) (7,725)

Continuing operations (6,195) (2,302) (7,576)
Acquisitions — — (149)

(6,195) (2,302) (7,725)
Interest receivable 470 110 514
Interest payable (1) (1) (1)

Loss on ordinary activities before taxation (5,726) (2,193) (7,212)
Tax credit on loss on ordinary activities 435 148 347

Loss on ordinary activities after taxation being
retained loss for the period (5,291) (2,045) (6,865)


Loss per share - basic and diluted 3 (5.5p) (3.1p) (9.0p)

All activities relate to continuing operations.

The Group has no recognised gains and losses other than the losses above and therefore no separate statement of total recognised gains and losses has been presented.



Consolidated balance sheet
as at 31 March 2002

31-Mar 31-Mar 30-Sep
Notes 2002 2001 2001
Unaudited Unaudited Audited
£000’s £000’s £000’s

Fixed assets
Intangible assets – goodwill 6,815 — 6,992
Tangible assets 974 474 740

7,789 474 7,732

Current assets
Debtors: amounts due after more than one year 2 435 — —
Debtors: amounts falling due within one year 784 644 976
Cash at bank and in hand 21,123 6,282 25,650

22,342 6,926 26,626
Creditors: Amounts falling due within one year (2,718) (662) (1,762)

Net current assets 19,624 6,264 24,864
Total assets less current liabilities 27,413 6,738 32,596
Creditors: Amounts falling due after more than one year (18) (2) —
Provisions for liabilities and charges (110) (7) (20)

Net assets 27,285 6,729 32,576



Capital and reserves
Called-up share capital 96 2 96
Share premium account 23,491 — 23,491
Other reserves 19,262 12,181 19,262
Profit and loss account (15,564) (5,454) (10,273)

Equity shareholders` funds 27,285 6,729 32,576




Consolidated cash flow statement
For the six months ended 31 March 2002

Six months ended Six months ended Year ended
31-Mar 31-Mar 30-Sep
2002 2001 2001
Unaudited Unaudited Audited
£000’s £000’s £000’s

Net cash outflow from operating activities (4,577) (2,133) (6,317)
Returns on investment and servicing of finance 447 110 470
Taxation — — 93
Capital expenditure (419) (442) (876)
Acquisitions and disposals — — 30

Cash outflow before management of liquid resources and financing
(4,549) (2,465) (6,600)
Management of liquid resources 3,726 (4,120) (22,700)
Financing 22 7,018 30,521

(Decrease) / increase in cash during the period (801) 433 1,221




Reconciliation of operating loss to net cash outflow from operating activities

Six months ended Six months ended Year ended
31-Mar 31-Mar 30-Sep
2002 2001 2001
Unaudited Unaudited Audited
£000’s £000’s £000’s

Operating loss (6,195) (2,302) (7,725)
Depreciation charge 179 75 259
Loss on sale of tangible fixed assets 6 — —
Amortisation of goodwill 177 — 140
Decrease / (increase) in debtors 192 (310) (483)
Increase in creditors 1,064 404 1,492

Net cash outflow from operating activities (4,577) (2,133) (6,317)


1 Basis of preparation
These accounts are unaudited and do not constitute statutory accounts within the meaning of section 240 of the Companies Act 1985. The interim results have been prepared on the basis of the accounting policies set out in the Report and Accounts for the year ended 30 September 2001, with the exception that FRS19 Deferred Tax has been adopted from the beginning of the period. The effect of adopting FRS19 is not material to the Group. The financial information relating to the year ended 30 September 2001 has been extracted from the full report and accounts which have been delivered to the Registrar of Companies. The report of the auditors on those accounts was unqualified.

2 Tax on loss on ordinary activities
The tax credit in the period of £435,000 has arisen as a result of the research and development expenditure claimed under the Finance Act 2000 and is subject to the agreement of the Inland Revenue. The amount is shown as a debtor due after more than one year.

3 Loss per share
The calculations of loss per share are based on the following losses and numbers of shares.

Six months ended Six months ended Year ended
31-Mar 31-Mar 30-Sep
2002 2001 2001
£000’s £000’s £000’s
Loss for the financial period 5,291 2,045 6,865


Number of shares Number of shares Number of shares
Weighted average number of shares 96,027,099 65,340,364 75,949,639


The weighted average number of shares for the 6 month period to 31 March 2001 has been adjusted for the bonus issue on 3 April 2001 where an additional 28 bonus shares were issued for every existing share.

Since the Group reported a net loss, diluted loss per share is equal to basic loss per share.

4 Analysis of changes in net funds

As at Cashflow As at
30-Sep-01 31-Mar-02
Audited Unaudited Unaudited
£000’s £000’s £000’s

Cash at bank and in hand 1,650 (801) 849
Finance leases (4) (22) (26)
Liquid resources 24,000 (3,726) 20,274

Total 25,646 (4,549) 21,097



Gruss,
Polecat

[Polecat]

!NEWS!


GW Raises £4.5 Million In New Share Issue To Commercialise Dispensing Technology
29/08/2002

GW Pharmaceuticals plc, the company licensed by the Home Office to develop prescription medicines from cannabis and other controlled drugs, announces that it has raised £4.47 million (£4.45 million net of expenses) through the issue for cash of 4,097,185 new ordinary shares (“the New Shares”).



Gruß,
Polecat

[Polecat]

REG-GW Pharmaceuticals <GWP.L> Issue of Equity
RNS Number:4982A
GW Pharmaceuticals PLC
29 August 2002


Embargoed until 0700 29 August 2002


GW Pharmaceuticals plc
("GW" or "the Company")

GW Raises £4.5 Million In New Share Issue To Commercialise
Dispensing Technology

GW Pharmaceuticals plc, the company licensed by the Home Office to develop
prescription medicines from cannabis and other controlled drugs, announces that
it has raised £4.47 million (£4.45 million net of expenses) through the issue
for cash of 4,097,185 new ordinary shares ("the New Shares"). The New Shares,
which represent 4.27% of GW`s issued share capital prior to the issue, were
issued at a price of £1.09 per share to funds managed by Troy Asset Management.
Proceeds from the share issue will be used primarily to support the
commercialisation of GW`s Advanced Dispensing System ("ADS") technology.

ADS is a novel secure drug dispensing technology which provides high levels of
security for dispensing drugs and also provides clinicians with the ability to
monitor drug use remotely. The ADS technology was originally developed by GW
for use with its cannabis-based medicines. GW recently announced that ADS is
being evaluated by the National Addiction Centre for use in the dispensing of
methadone and diamorphine in the treatment of drug addiction. The ADS technology
has been endorsed by the Home Office and has broad commercial potential.

Dr Geoffrey Guy, Executive Chairman of GW, commented: "The demonstration of GW`s
Advanced Dispensing System earlier this summer has generated a considerable
amount of interest and enthusiasm from investors and physicians alike.

"The newly developed ADS technology presents opportunities over and above our
medicinal cannabis programme. We therefore felt it prudent to raise additional
funds now to capture the full potential of this new and exciting part of our
business. The additional £4.5 million investment increases our total cash
balance to approximately £21 million and further enhances GW`s strong financial
position."

Application will be made for the New Shares to be admitted to the Alternative
Investment Market. Such admission is expected to become effective on 4
September 2002.

- Ends -

Enquiries:

GW Pharmaceuticals plc (29/08/02) 020 7950 2800
Dr Geoffrey Guy, Executive Chairman (Thereafter) 01980 557 000
Justin Gover, Managing Director

Weber Shandwick Square Mile 020 7950 2800
Kevin Smith/Graham Herring


This information is provided by RNS
The company news service from the London Stock Exchange

[Polecat]

GW Pharmaceuticals plc ("the Company")

Further to the anouncement made by the Company on 29th August 2002 in relation
to the issue of new shares to funds managed by Troy Asset Management, the
Company received notice yesterday, under section 198 of the Companies Act 1985,
disclosing the following interest in the share capital of the Company:

Michael Lester, as trustee of certain family trusts, acquired 3,200,000 ordinary
shares of 0.1p each in the Company on 4th September 2002 at 1.09p per share.
These shares are registered in the name of Adam & Company Nominees. Following
this transaction Michael Lester has a notifiable interest of 3,200,000 ordinary
shares representing 3.2% of the issued share capital of the Company.

6th September 2002


This information is provided by RNS
The company news service from the London Stock Exchange

[Polecat]

!!!NEWS!!!

30 September 2002

Release of Positive Data from Completed Phase II Pain Trial

GW Pharmaceuticals plc, the pharmaceutical company developing a portfolio of non-smoked cannabis-based prescription medicines, announces the latest Phase II data from a completed 34 patient study in patients with Multiple Sclerosis (“MS”), Spinal Cord Injury and other conditions, suffering primarily from severe pain. This new data represents the largest patient study presented to date by GW and demonstrates significant benefits for patients, notably in the relief of pain and improvement in sleep.

The data was presented by Dr Willy Notcutt, James Paget Hospital, Great Yarmouth, at the American Academy of Pain Management in Reno, Nevada, USA on Saturday 28 September 2002.

In his pain clinic, Dr Notcutt examined 34 patients with severe symptoms resulting from MS, Spinal Cord Injury and other medical conditions which could not be treated satisfactorily with current medications. The placebo-controlled trial included three different cannabis-based medicines. Of the 34 patients, 28 obtained benefit or significant benefit and elected to continue on to a long-term trial. Twenty-five are still on that trial, a number of which have been taking the medication for over 2 years. Only six of the patients obtained no benefit from the medication.

Dr Geoffrey Guy, Executive Chairman of GW, commented, “We are delighted with the results of this study in patients with severe pain. The data shows improvements with all three of our cannabis-based medicines and we therefore believe that there will be a market for all three medicines in pain treatment in due course.

“Separately, I am also pleased to report that patient recruitment and data analysis for a number of our Phase III trials has proceeded ahead of schedule. We now expect to announce preliminary Phase III results in November.”

Commenting on his Phase II trial data, Dr Notcutt said, “Patients in this trial are suffering from severe pain - it dominates their lives. Given the previously intractable nature of their pain symptoms, the improvements provided by cannabis-based medicines are all the more remarkable. Many of those with chronic pain also suffer from a poor quality of sleep, which – over time – can have profoundly negative effects on them and their families. By bringing about improvements in their sleep regime, as well their pain, we can have a major positive impact on their quality of life.”

The Phase II trial employed a ‘within patient randomised double-blind placebo-controlled crossover’ design. All patients received three different cannabis-based medicines characterised by different content of cannabinoids, the active molecules unique to the cannabis plant, and placebo. The medicines investigated were a THC-rich product, a CBD-rich product and an equal ratio THC:CBD product. During the trial, patients remained on all their current medication, hence any changes against placebo may be considered to be improvements over and above that which could be achieved with their current medication.

In the 34 patients, statistically highly significant lower mean overall symptom scores were observed with the THC:CBD product, THC product and CBD product compared to placebo. The positive CBD result is of particular interest as CBD is a non-psychoactive component of cannabis that was generally thought to have primarily anti-inflammatory rather than analgesic qualities. This corroborates the evidence for CBD analgesic activity from a pilot study in Oxford, which was reported by Dr Philip Robson, Medical Director of GW, at a meeting of the International Cannabinoid Research Society in California in July.

A separate analysis of only the 16 patients with MS also confirmed a statistically highly significant reduction in symptom scores using the THC:CBD product and THC product.

Highly significant improvements in both sleep quality and sleep duration were also observed with both the THC:CBD and THC products compared with placebo.

All the products were very well tolerated. The adverse event profile across all GW’s Phase II trials, including patients from this study, shows a significantly lower incidence of side effects for the THC:CBD product compared with the THC product.


Gruß,
Polecat

[Polecat]

5th November 2002

GW Announces Positive Results From Each of Four Phase Three Clinical Trials

GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, is today announcing preliminary results from its first four completed Phase III clinical trials.

The key points of the results can be summarised as follows:

GW’s four randomised, double-blind, placebo-controlled Phase III trials included approximately 350 patients suffering from Multiple Sclerosis and neuropathic pain
Each of the four trials reported positive data, including statistically significant reductions in neuropathic pain, spasticity and sleep disturbance
As a result of these positive results, GW now intends to submit its first regulatory application to the Medicines Control Agency early next year
Subject to regulatory approval, the UK market launch of GW’s first cannabis-based medicine could now be in 2003
Dr Geoffrey Guy, Executive Chairman of GW, said: “These preliminary Phase III results represent a major milestone in the pharmaceutical development of cannabis-based medicines. The performance of GW’s medicine has exceeded our own expectations and holds out the prospect of providing a significant advance in the treatment of these most challenging of medical conditions. Subject to regulatory approval, we are now on track to deliver our first prescription medicine to the UK market next year.”

Enquiries:

GW Pharmaceuticals plc
Dr Geoffrey Guy, Executive Chairman
Justin Gover, Managing Director
Mark Rogerson, Press and PR (05/11/02) 020 7950 2800
(Thereafter) 01980 557000

07885 638810

Weber Shandwick Square Mile
Kevin Smith/Graham Herring 020 7950 2800



GW Announces Positive Results From Each of Four Phase Three Clinical Trials

GW Pharmaceuticals plc, the company developing a portfolio of non-smoked cannabis-based prescription medicines, announces positive preliminary results from each of four completed Phase III clinical trials in patients suffering from Multiple Sclerosis and neuropathic pain. As a result of these positive results, GW now intends to submit its first regulatory application to the Medicines Control Agency early next year. Subject to regulatory approval, the UK market launch of GW’s first cannabis-based medicine could be achieved during 2003.

GW’s four randomised, double-blind Phase III trials included approximately 350 patients and are part of the largest clinical programme ever undertaken into the medicinal effects of cannabis. The trials examined, in comparison to placebo, the effectiveness of GW’s whole plant medicinal cannabis extract containing tetrahydrocannabinol (THC) and cannabidiol (CBD) as its principal components. The THC:CBD medicine was administered by means of a spray into the mouth.

In the trials, the THC:CBD medicine achieved statistically significant reductions in neuropathic (nerve-damage) pain, as well as statistically significant improvements in other symptoms of Multiple Sclerosis (“MS”), most notably spasticity and sleep disturbance. These findings are consistent with results from Phase II trials previously announced by the Company.

The four trials examined the efficacy of the THC:CBD product in relieving symptoms in the following conditions:

Neuropathic pain in MS
Pain and sleep disturbance in MS and other neurological conditions
Multi-symptoms in MS
Neuropathic pain in Brachial Plexus Injury
The main summary findings from each of the studies, the full results of which will be submitted for peer-review publication in due course, are provided below. Results quoted as ‘statistically significant’ had an associated probability value (p-value) of less than 0.05, whilst those that are ‘highly statistically significant’ had a p-value less than 0.01.

In a double-blind parallel group study comparing the efficacy of GW’s THC:CBD product with placebo in the treatment of neuropathic pain in 66 patients with MS, the THC:CBD medicine provided highly statistically significant relief of pain in comparison with placebo and highly statistically significant reduction in sleep disturbance.

In a double-blind parallel group study comparing the efficacy of GW’s THC:CBD product with placebo in the treatment of chronic refractory pain in 70 patients with MS and other neurological conditions, the THC:CBD medicine provided statistically significant pain relief (as evidenced by the diminished use of analgesic rescue medication) and statistically significant reduction in sleep disturbance.

In a double-blind parallel group study comparing the efficacy of GW’s THC:CBD product with placebo in the treatment of a number of symptoms in 160 patients with MS, the THC:CBD medicine provided a highly statistically significant improvement in the symptom of spasticity. Positive trends were also observed in a number of other MS symptoms (providing useful additional support to significant results obtained in Phase II trials).

In a double-blind crossover study comparing the efficacy of GW’s THC:CBD product, GW’s THC alone product and placebo in the treatment of neuropathic pain in 48 patients with Brachial Plexus Injury, both the THC:CBD medicine and the THC medicine provided highly statistically significant relief of pain and statistically significant reduction in sleep disturbance. Brachial plexus injury is a rare but particularly challenging cause of intractable neuropathic pain, and to the best of our knowledge this is the first placebo-controlled trial ever conducted in this condition.

The benefits seen in all four studies are all the more notable in that they represent improvements over and above that which patients obtain with their standard prescription medicines (patients receiving both active and placebo medicines continued to take their standard prescription medicines during the trial).

In addition, the trials have demonstrated that GW’s cannabis-based medicine has an excellent safety profile. Self-titration (adjustment) of their dose enabled most patients to achieve improvement in their symptoms without incurring a level of unwanted effects which would interfere with day-to-day living.

Commenting on the trial results, Dr Philip Robson, Medical Director of GW, said “These rigorous randomised placebo-controlled trials indicate that GW’s cannabis-based medicine can provide additional benefits over and above that of standard treatments in these serious and refractory neurological conditions. The results show statistically significant reductions in neuropathic pain, which is recognised as being difficult to treat and is often particularly distressing. There were also significant improvements in other symptoms in patients with MS, notably spasticity and sleep disturbance. In my opinion, it is this broad spectrum of activity, coupled with an excellent safety profile, which gives GW’s cannabis-based medicine the potential to make a unique contribution towards improving the quality of life of patients with these chronic disabling diseases.”

In addition to the four completed trials, GW has a further five Phase III trials in progress. These further studies are examining other potential areas of medical benefit for cannabis-based medicines, including pain in cancer and spinal cord injury, and are expected to complete during 2003. Including these further five studies, GW’s clinical programme will have included over 1000 subjects.

GW’s first regulatory submission will provide evidence of efficacy generated from the positive results from the four completed Phase III clinical trials as well as positive results previously reported from a number of Phase II trials. Safety data will include approximately 350 accumulated patient-years of exposure to the medicine.

Over the past several years, the UK Government has consistently stated that, should a prescription cannabis-based medicine be developed which meets the rigorous standards applied by the Medicines Control Agency, it will amend the legislation so that such a medicine is available for patients.


- Ends -

Notes on trial data:

In the neuropathic pain trials, pain was measured using a Box Scale 11 (BS11) pain scale. In the chronic refractory pain trial, patients were permitted to use escape analgesia, hence pain relief is assessed by the frequency of use of such escape medication.
Sleep disturbance was measured in the trials using a BS11 scale as well as other numeric scales.
In the MS symptoms trial, spasticity and other target symptoms were assessed by a 100mm Visual Analogue Scale (VAS).

----

Gruß,
Polecat

[Polecat]

Einen schönen Gruß an alle Mitinvestierten!

Ich wollte nur mal eben eine Art Jahresbilanz ziehen. Diesen Thread gibt es nun knapp über ein Jahr und wer von Anfang an dabei ist, kann zur Zeit etwa 150% Gewinn einfahren. Ich für meinen Teil habe bisher noch kein Stück verkauft und werde dies auch weiterhin nicht tun, habe allerdings einen "Stop-Loss" (obwohl der Begriff hier ja eigentlich "Stay-profitable" heißen müßte )
bei 2€ gesetzt.

Die Aussichten für dieses Unternehmen sind in meinen Augen weiterhin sehr positiv, sodass ich eher zum Nachlegen oder Einstieg raten würde.

Wer ist denn alles noch oder neu dabei, wenn man mal ins Board horchen darf?

Gruß,
Polecat

[Polecat]

[Polecat]

15 January 2003
Preliminary Results for the Year Ended 30 September 2002

GW Pharmaceuticals plc, the company licensed by the UK Home Office to work with cannabis and a range of controlled drugs for medical research purposes, announces its preliminary results for the year ended 30 September 2002.

Highlights

Regulatory dossier to be submitted to the Medicines Control Agency in first quarter of 2003
Target timescale for first product launch brought forward from 2004 to 2003
Commercial discussions underway with potential marketing and distribution partners in a number of territories
Scale-up process for commercial production complete
Positive results from four Phase III clinical trials in Multiple Sclerosis and Neuropathic Pain
Five additional Phase III clinical trials ongoing, including pain in cancer and spinal cord injury
Launch of Home Office-backed initiative in drug addiction treatment to develop methadone and diamorphine products in conjunction with GW’s proprietary dispensing technology
Net loss for year in line with expectations at £11.2 million
Year end cash resources £20.2 million
Dr Geoffrey Guy, Executive Chairman, commented: “This has been a year which has seen GW achieve its most important milestones to date. In particular, the positive results from four Phase III clinical trials take GW a major step closer to the launch of the Group’s, and the world’s, first non-smoked prescription cannabis-based medicine. Originally anticipated to take place in 2004, we are now planning for a possible launch during 2003.

“We have a great deal to look forward to in the coming year. In the UK, we are on track to submit the regulatory application for our first product in the first quarter of 2003. Subject to regulatory approval, we anticipate initial UK market launch towards the end of the year. Discussions are now underway with a number of pharmaceutical companies regarding the commercialisation of GW’s initial products around the world. We also look forward to the results of more Phase III trials which are intended to expand the market for the initial product. At the same time, we aim to report continuing progress with the clinical trials in our anti-addiction programme.”

A presentation for analysts is taking place today at 09.30 at Weber Shandwick Square Mile, Fox Court, 14 Gray’s Inn Road, London WC1. An audio webcast of the presentation will be available on GW’s website at www.gwpharm.com from 15.00 today.

Enquiries:

GW Pharmaceuticals plc
Dr Geoffrey Guy, Executive Chairman
Justin Gover, Managing Director
(15/01/03) 020 7067 0700
(Thereafter) 01980 557000



Weber Shandwick Square Mile
Kevin Smith/Graham Herring 020 7067 0700

[Polecat]

!NEWS!

22 January 2003
GW TO DEVELOP NEW CANNABINOID OPPORTUNITIES WITH PROFESSOR RAPHAEL MECHOULAM

GW Pharmaceuticals plc, the company developing a portfolio of non-smoked, cannabis-based prescription medicines, has established an extensive research collaboration with Professor Raphael Mechoulam, from the Hebrew University of Jerusalem, Israel, one of the world’s leading cannabinoid scientists.

Under the agreement, signed with Yissum, the Research Development Company of the Hebrew University of Jerusalem, GW has acquired the rights to a number of important cannabinoid patents invented by Professor Mechoulam. The company will be working closely with him and his team for the next three years to develop these new opportunities in furtherance of its scientific and commercial activities. The patents include inventions relating to cannabidiol (CBD), one of the cannabinoids on which GW’s research is focused, and endocannabinoids (cannabinoids found in the human body).

In collaboration with GW, Professor Mechoulam will be researching the pharmacology of the phytocannabinoids and the cannabinoid system in humans. He will also act as a consultant on GW’s research into synthetic cannabinoids (cannabinoids created in the laboratory).

Dr Geoffrey Guy, Executive Chairman of GW, said “Professor Mechoulam’s knowledge of cannabinoids is second to none and we are delighted to be building this relationship with him and his team. We look forward to an exciting and fruitful collaboration.”

Last year, GW established the Cannabinoid Research Institute (CRI) under the direction of Dr Philip Robson. The CRI is intended to consolidate the company’s position as a world leader in the development of cannabinoid medicines. In addition to Professor Roger Pertwee, GW’s Director of Pharmacology, Professor Mechoulam will become an integral member of GW’s primary research team at the CRI.



Editors Notes
Professor Raphael Mechoulam is Professor of Medicinal Chemistry at the Hebrew University of Jerusalem and has been working on cannabinoid chemistry since the early 1960s. It was he who coined the term “cannabinoid”. In 1964, Professor Mechoulam’s laboratory first identified and synthesized delta-9-tetrahydrocannabinol (“THC”), the main psychoactive component of cannabis. Since then, his team has gone on to identify the structure of most of the cannabinoids and metabolites and to discover the endogenous cannabinoids anandamide and 2-arachidonylglycerol (2-AG), which occur naturally in the body.

Professor Mechoulam is the author of more than 270 publications and an inventor on over 21 patents, including several synthetic cannabinoids. He is past president of the International Cannabinoid Research Society (ICRS), which in 1999 established The R Mechoulam Award in Cannabinoid Research in his honour. He has received numerous prizes and honours from countries around the world in recognition of his achievements and outstanding contribution to the field of cannabinoid research.

Yissum is the research development company of the Hebrew University and a wholly-owned subsidiary of the university.

[Polecat]

Weiß zwar nicht, ob GW da mit drinhängt, ist aber trotzdem nicht uninteressant...

Montag 3. Februar 2003, 11:00 Uhr
Cannabis-Spray lindert Schmerzen
Berlin (LIFELINE) - Im englischen Norfolk haben Ärzte erstmals ein Cannabis-Spray bei Schmerzpatienten eingesetzt. Die Ergebnisse seien vielversprechend, berichtet BBC News Online.

"Einige der Patienten sagten uns, sie hätten mit Hilfe des Sprays so gut geschlafen, wie seit Jahren nicht mehr", erklärt Dr. William Nottcutt, der Leiter der dortigen Schmerzambulanz. Der Mediziner hofft nun, dass die britische Gesundheitsbehörde das Medikament lizenziert und es so in Zukunft problemlos auf Rezept erhältlich sein wird.

Erprobt wurde das Cannabis-Spray an 600 Patienten mit Multipler Sklerose, Rückenmarks-Schädigungen, sonstigen Nerven-Verletzungen oder Tumorschmerzen. (red)

Quelle: http://de.news.yahoo.com/030203/180/39giu.html

Gruß,
Polecat

[Polecat]

GW Pharmaceuticals plc
(“GW” or “the Company”)

Submission of Regulatory Application to MCA

GW announces that the regulatory dossier for the Company’s first cannabis-based prescription medicine has been submitted to the UK Medicines Control Agency as planned.

- ENDS -

GW Pharmaceuticals plc 01980 557000
Dr Geoffrey Guy, Chairman
Justin Gover, Managing Director

Weber Shandwick Square Mile 020 7067 0700
Kevin Smith/Graham Herring


Diese Nachricht ist vom 31.03.2003 und auf der GW-Homepage nachzulesen: http://www.gwpharm.com

Dort zu finden ist auch der aktuelle Quartalsbericht: http://www.gwpharm.com/pdf/02_ar.pdf


und hier noch ein Kommentar der Company auf ein paar Presseberichte:

3rd February 2003

Response to Media Comment

GW notes recent media comments relating to its commercialisation discussions.

The Company has consistently stated its commercial strategy to be to enter into partnerships following Phase III trial results in order to secure optimum commercial terms. In its preliminary results statement of 15 January 2003, GW announced that, having reported positive results from four Phase III trials, the Company is presently in active discussions with a number of pharmaceutical companies regarding the commercialisation of its range of products.

These discussions are continuing as planned and there have been no events since the Company``s recent announcements which alter the target timescales for concluding GW``s first commercial partnership arrangement. GW remains on track to sign its first commercial arrangements during the first half of 2003, as indicated throughout last year and in the Company``s recent preliminary results statement.

The Company is scheduled to submit its regulatory application to the Medicines Control Agency during the first quarter of 2003. Subject to regulatory approval, GW aims to launch its first product in the UK towards the end of 2003.



Bin ich hier eigentlich Alleinunterhalter oder freut sich jemand mit mir über die Kurssteigerungen und die guten Aussichten der Firma?

Gruß ... falls ihn jemand mitbekommt ,
Polecat

[Klick2003]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]